Image Source
.....
Hepatitis C treatment cures over 90 percent of patients who also have cirrhosis
Date:
April 12, 2014
Source:
University of Texas Health Science Center at San Antonio
Summary:
Twelve
weeks of an investigational oral therapy cured hepatitis C infection in
more than 90 percent of patients with liver cirrhosis and was well
tolerated by these patients, according to a new study.
Twelve
weeks of an investigational oral therapy cured hepatitis C infection in
more than 90 percent of patients with liver cirrhosis and was well
tolerated by these patients, according to an international study that
included researchers from UT Medicine San Antonio and the Texas Liver
Institute. Historically, hepatitis C cure rates in patients with
cirrhosis (liver scarring) have been lower than 50 percent and the
treatment was not safe for many of these patients.
Hepatitis
C virus is the No. 1 driver of cirrhosis, liver transplants and liver
cancer in the United States, noted Fred Poordad, M.D., lead author on
the study, which was released Saturday by The New England Journal of Medicine
in conjunction with Dr. Poordad's presentation of the data at the
International Liver Congress in London. UT Medicine is the clinical
practice of the School of Medicine at The University of Texas Health
Science Center at San Antonio, where Dr. Poordad is a professor of
medicine. He is vice president of the Texas Liver Institute in San
Antonio.
Interferon previously was the only agent to show effectiveness against hepatitis C, but patients often relapsed and the therapy caused multiple side effects. The new regimen is interferon-free and consists of several agents -- ABT-450/ritonavir, ombitasvir, dasabuvir and ribavirin. Twelve weeks after the last dose, no hepatitis C virus was detected in the bloodstream of 91.8 percent of patients who took the pills for 12 weeks. Among patients treated for 24 weeks, 95.9 percent were virus-free 12 weeks after the end of therapy.
Read More Here
Interferon previously was the only agent to show effectiveness against hepatitis C, but patients often relapsed and the therapy caused multiple side effects. The new regimen is interferon-free and consists of several agents -- ABT-450/ritonavir, ombitasvir, dasabuvir and ribavirin. Twelve weeks after the last dose, no hepatitis C virus was detected in the bloodstream of 91.8 percent of patients who took the pills for 12 weeks. Among patients treated for 24 weeks, 95.9 percent were virus-free 12 weeks after the end of therapy.
Read More Here
No comments:
Post a Comment
Hello and thank you for visiting my blog. Please share your thoughts and leave a comment :)